Pierre Fabre Pharmaceuticals and Atara Biotherapeutics resubmitted Ebvallo (tabelecleucel) to the FDA after the agency previously rejected the therapy twice. The resubmission targets a fatal complication of Epstein-Barr virus in transplant patients and follows prior CRLs tied to both manufacturing-inspection concerns and, later, perceived insufficiency of clinical evidence from the pivotal single-arm ALLELE study. Analysts cited in the report indicate the new package could land as a Class 2 BLA resubmission, potentially shifting the path forward toward a targeted action date in 2027. The partners say GMP and quality issues have been resolved and that interpretability concerns have been addressed with expanded supporting information, including data from expanded-access programs and commercial use in Europe. For cell-therapy developers, the case reflects the continuing importance of regulatory alignment after leadership changes at the FDA and how resubmissions can become a second, time-consuming battleground after initial denials.